Characterization of Parvovirus B19 Genotype 2 in KU812Ep6 Cells
Open Access
- 15 November 2005
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (22) , 14197-14206
- https://doi.org/10.1128/jvi.79.22.14197-14206.2005
Abstract
An infectious parvovirus B19 (B19V) genotype 2 variant was identified as a high-titer contaminant in a human plasma donation. Genome analysis revealed a 138-bp insertion within the p6 promoter. The inserted sequence was represented by an additional 30 bp from the end of the inverted terminal repeat adjacent to a 108-bp element found also, in inverted orientation, at the extreme right end of the unique sequence of the genome. However, despite the profound variations in the promoter region, the pattern of gene expression and DNA replication did not differ between genotype 1 and genotype 2 in permissive erythroid KU812Ep6 cells. Capsid proteins of both genotypes differ in their amino acid sequences. However, equivalent kinetics of virus inactivation at 56°C or pH 4 indicated a comparable physicochemical stability of virus capsids. Sera from six individuals infected by B19V genotype 1 were investigated on cross-neutralization of B19V genotype 2 in vitro. Similar neutralization of both B19V genotypes was observed in sera from three individuals, while the sera from three other individuals showed weaker cross-neutralization for genotype 2. In conclusion, the in vitro replication characteristics and physical stability of B19V capsids are very similar between human parvovirus B19 genotypes 1 and 2, and cross-neutralization indicates a close antigenic relation of genotypes 1 and 2.Keywords
This publication has 29 references indexed in Scilit:
- Recurrent high level parvovirus B19/genotype 2 viremia in a renal transplant recipient analyzed by real‐time PCR for simultaneous detection of genotypes 1 to 3Journal of Medical Virology, 2004
- Different susceptibility of B19 virus and mice minute virus to low pH treatmentTransfusion, 2004
- Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2Thrombosis and Haemostasis, 2004
- Prevalence of Parvovirus B19 in Liver Tissue: No Association with Fulminant Hepatitis or Hepatitis‐Associated Aplastic AnemiaThe Journal of Infectious Diseases, 2003
- Parvovirus B19 transmission by heat‐treated clotting factor concentratesTransfusion, 2002
- Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniquesVox Sanguinis, 2002
- Large-Scale Screening for Human Parvovirus B19 DNA by PCR: Application to the Quality Control of Plasma for FractionationVox Sanguinis, 2000
- Report of a Collaborative Study to Establish the International Standard for parvovirus B19 Serum IgGBiologicals, 1997
- Beitrag zur kollektiven Behandlung pharmakologischer ReihenversucheNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1931
- THE METHOD OF ‘RIGHT AND WRONG CASES’ (‘CONSTANT STIMULI’) WITHOUT GAUSS'S FORMULAEBritish Journal of Psychology, 1904-1920, 1908